Click to View AWARD CRITERIA
INVENTOR OF THE YEAR
A qualified Nominee is an inventor who, by a single invention or multiple innovations, has created the greatest impact on technology through his, her or their innovation(s).
Dr. Winter is a founder and interim CEO of Core Quantum Technologies (CQT), an OSU technology commercialization company. CQT’s technologies are based on her work as an Associate Professor in Chemical and Biomolecular Engineering and Biomedical Engineering at OSU and consists of nanoparticle materials for biomedical applications.
Dr. Winter is the author of > 30 journal articles, 4 provisional patents, and 1 full US/PCT patent application. Under the guidance of Dr. Winter and her team, CQT finished 1st in the OSU business plan competition, has received a prestigious ICorp grant from the National Science Foundation, and has raised over $320k in funding since January of this year.
Dr. Marras is a pioneer who employs engineering techniques to better understand the causal pathways associated with low back disorder. Over the past 30 years, Professor Marras has developed a strong research foundation that quantifies low back risk exposures and spine tissue loading to understand the complex interactions within the spine. These assessments have resulted in quantifiable measures that describe the extent of low back pain as well as a quantification of the likely source of a low back disorder.
This work has resulted in the development of commercially available assessment tools (lumbar motion monitor or LMM) as well as personalized predictive models that can be used by health professional to better understand the impact of spine treatments for a specific individual. Through these efforts, industry has been able to save million of dollars in injury costs and surgeons have begun to use these techniques to better plan treatments and surgical interventions.
Dr. Kuppusamy is a professor in the department of medicine/cardiovascular division at The Ohio State University, Columbus.
His innovation involves the development of a novel technology including oxygen-sensing probes and device for fast, accurate, and reliable measurement of oxygen (oximetry) in tissues. The technology is built upon the principle of electron paramagnetic resonance (EPR), which uses magnetic field-based detection of the oxygen sensor and oxygen. Although EPR has been known for over 60 years, the use of it for tissue oxygen measurement in the clinical setting was limited due to a number of barriers, most important of which is the lack of high-sensitive oxygen probes. The discovery of paramagnetic crystalline sensors by his laboratory made a breakthrough in the adaptation of the EPR technology for useful clinical applications.
EWI is an international thought leader on materials joining and allied technologies. It uses manufacturing technology innovation to increase the competitiveness of over 1,200 member locations of global leaders in the advanced energy, aerospace, automotive, government/defense, heavy manufacturing, oil and gas, and consumer products industries.
AcousTech Machining combines the company’s unique expertise in high-power ultrasonics with traditional machining operations to significantly increase material removal rates, reduce tool wear, reduce coolant usage, and reduce operating loads. The AcousTech Machining Module employs the use of an acoustically tuned tool holder to transmit 20-kHz vibrations to conventional metalworking tools. A key development of EWI’s AcousTech Machining Module has been the ability to transmit acoustical vibrations through conventional metalworking tools while isolating ancillary vibrations from the machine spindle or structure. Matt Short is well recognized for his diverse background in the fields of ultrasonics, automated system design, tool and die design, and CNC/CAM programming. His expertise has provided distinguishable advantages for EWI’s member companies with the implementation of new technology into production systems.
Scott Greiff is particularly qualified to be this year’s Inventor of the Year because of his work on his breakthrough email utility app for iOS, MailTamer.
Scott was able to identify a ubiquitous common concern like email management, and then hone in on a solution to the management of large accumulations of messages.
Nanofiber Solutions is a medical device manufacturer of three-dimensional (3-D) scaffolds and cell culture products that advance biological sciences. These medical devices are based on very small polymer fibers called nanofibers, that are made into synthetic organs and implanted into the body to replace damaged organs.
Jed Johnson designed and built the first in man synthetic nanofiber trachea that has been implanted into four humans across the world, with our first US surgery scheduled to occur in late 2012. This platform technology has proven very successful with the tracheal transplants and we are aggressively applying the nanofiber technology to other areas of medical implants with 8 patent filings in 2012 alone.
QuTel, which stands for QUantum Tunneling ELectronics Inc. opens a new paradigm of computing. QuTel is a dramatic shift to ultra-low voltage, ultra-low power operation for semiconductor devices, enabling a dramatic improvement in reduced power consumption over current CMOS (Complementary Metal Oxide Semiconductor) technologies.
We are at the dawn of the era of personalized medicine where our genome sequence will be used to define clinical treatment. Through utilization of state-of-the-art technologies, Dr. White’s team at the Research Institute at Nationwide Children’s Hospital is capable of sequencing the human genome in days, enabling them to search for the genetic causes of congenital heart disease, muscular dystrophy, autism and rare genetic syndromes. However, the terabytes of data these next-generation sequencers produce has created an informatics bottleneck in which current approaches take months to complete analysis and interpretation. To overcome this “big data” challenge, Dr. White discovered a revolutionary computational approach that enabled development of “Churchill”, genome analysis software that fully automates the genome analysis process. Compared with alternative analysis pipelines, Churchill is more accurate, meets clinical sequencing standards, simple to implement both in-house and on the “Cloud”, and drastically reduces the analysis time from weeks to under two hours. As increasing numbers of molecular diagnostic laboratories implement next generation sequencing in clinical settings, Churchill provides an immediate solution to the data analysis challenges these laboratories face.
Sensetronics seeks commercialization of immunoHFET (heterojunction field effect transistor) sensors for detection of protein analytes in medicine. ImmunoHFET technology deploys an affinity reagent (antibody or other) on a field effect transistor surface, and the immunoHFET detects analytes bound thereby by the changes in the electrical properties of the underlying HFET induced by bound analyte electric fields.
Our group discovered and documented that immunoHFETs operated at physiologic salt concentrations (150mM Na+) were feasible, contrary to conventional wisdom prevalent in the field at the time. Development of successful immunoHFET sensors required interfacial layers and interfaces that were engineered to minimize nanometer distance between bound analytes and sensor sensing channels. The centrality of neither of these objectives were fully recognized nor rigorously pursued by previous investigators, with the result that prior attempts to provide immunoFETs suitably sensitive for clinical use were not successful. However, incorporation of these nuances allowed us to demonstrate successful immunoHFET sensors operating in in vivo conditions.
Dr. Marashdeh is the cofounder, President & CEO of Tech4Imaging LLC, a start-up Company from The Ohio State University. He currently hold two patents and has published tens of publications related our technology and its applications. His innovation is related to Electrical Capacitance Volume Tomography (ECVT), an imaging technology that can be deployed to various applications. His efforts have revolutionized the field of capacitance tomography as ECVT technique has the potential to revolutionize the energy, aerospace, chemical, and healthcare industries.
He has been involved in every stage of the development and commercialization of electrical capacitance volume tomography. Applications for ECVT include power-plant operations, combustion imaging, and multi-phase flow systems. Tech4Imaging was able to develop a commercial prototype through government grants, and we currently have several ECVT sensors installed at the National Energy Technology Laboratory. Our technology has a global reach that is best demonstrated by sales to Australia and Japan over the past year. ECVT technology and its potential were highlighted recently in a press release from the US Department of Energy.
Personalized medicine is a central theme of the Ohio State University. Dr. Sadee has developed the OSU Program in Pharmacogenomics aimed at discovery of genetic variation affecting treatment outcomes for the individual patient, funded by a $10 million NIH grant.
With novel genomics methodologies, we have tackled a seemingly insurmountable hurdle: identifying hidden genetic variants germane to the success or failure of drug therapy. Our novel approach has revealed multiple genetic variants influencing drug therapy of cardiovascular disease, CNS disorders, and cancer. These genetic variants, affecting gene regulation rather than the expressed protein, had long been neglected but have proven transformative in our understanding of human nature. Multiple patent applications are pending, with early clinical applications already initiated, and efforts to establish a biotech company ongoing. Our research results aim at developing drug-companion diagnostics (or “theranostics”) where a drug is coupled with a diagnostic marker to assure optimal response in a given patient. While still in infancy, theranostics are considered a main future direction of medicine; indeed, a companion diagnostic may equal the value of a new drug compound.